Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Iclusig“
Suchtreffer
Begriffe & Kennungen
Iclusig · 4.8 · Description of selected adverse reactions
Eintrag öffnenIclusig · 4.8 · Description of selected adverse reactions
Eintrag öffnenIclusig · 4.8 · Discontinuation due to myelosuppression was infrequent (thrombocytopenia 4%, neutropenia and anaemia < 1% each
Eintrag öffnenIclusig · 4.8 · Discontinuation due to myelosuppression was infrequent (thrombocytopenia 4%, neutropenia and anaemia < 1% each
Eintrag öffnenIclusig · 4.8 · Hepatitis B reactivation Hepatitis B reactivation has been reported in association with BCR-ABL TKIs. Some cas
Eintrag öffnenIclusig · 4.8 · Hepatitis B reactivation Hepatitis B reactivation has been reported in association with BCR-ABL TKIs. Some cas
Eintrag öffnenIclusig · 4.8 · Hepatotoxicity Events of hepatotoxicity occurred in 64% of patients who have received ponatinib in combination
Eintrag öffnenIclusig · 4.8 · Hepatotoxicity Events of hepatotoxicity occurred in 64% of patients who have received ponatinib in combination
Eintrag öffnenIclusig · 4.8 · In the OPTIC phase 2 trial (see section 5.1) with a median 77.9 months follow-up, arterial cardiovascular, cer
Eintrag öffnenIclusig · 4.8 · In the OPTIC phase 2 trial (see section 5.1) with a median 77.9 months follow-up, arterial cardiovascular, cer
Eintrag öffnenIclusig · 4.8 · In the PACE phase 2 trial (see section 5.1) with a minimum 64-month follow-up, arterial cardiovascular, cerebr
Eintrag öffnenIclusig · 4.8 · In the PACE phase 2 trial (see section 5.1) with a minimum 64-month follow-up, arterial cardiovascular, cerebr
Eintrag öffnenIclusig · 4.8 · In the PhALLCON phase 3 trial (see section 5.1) with a median 20.43 months follow up, arterial cardiovascular,
Eintrag öffnenIclusig · 4.8 · In the PhALLCON phase 3 trial (see section 5.1) with a median 20.43 months follow up, arterial cardiovascular,
Eintrag öffnenIclusig · 4.8 · Myelosuppression In the PACE Study, myelosuppression was commonly reported in all patient populations. The fre
Eintrag öffnenIclusig · 4.8 · Myelosuppression In the PACE Study, myelosuppression was commonly reported in all patient populations. The fre
Eintrag öffnenIclusig · 4.8 · Myelosuppression events were reported in 83% of ponatinib-treated patients in PhALLCON, 63% of ponatinib-treat
Eintrag öffnenIclusig · 4.8 · Myelosuppression events were reported in 83% of ponatinib-treated patients in PhALLCON, 63% of ponatinib-treat
Eintrag öffnenIclusig · 4.8 · Paediatric population The safety of ponatinib monotherapy in paediatric patients has been evaluated in a phase
Eintrag öffnenIclusig · 4.8 · Paediatric population The safety of ponatinib monotherapy in paediatric patients has been evaluated in a phase
Eintrag öffnen